12/03/2024 | Press release | Distributed by Public on 12/03/2024 15:23
Item 1.01 | Entry into a Material Definitive Agreement |
On December 2nd, 2024 Stemtech (the Company) executed a Merger Agreement with Seacret Direct/Viago by which Seacret/Viago shall be merged into Stemtech. Stemtech valued the acquisition of Seacret at $32.5 million dollars and issued this value of its shares as consideration. The two companies are in a similar health space, and their combined value is seen as a benefit to both as well as shareholders.